Search

Your search keyword '"Cedric Lecaille"' showing total 9 results
Start Over Author "Cedric Lecaille" Journal annals of oncology
9 results on '"Cedric Lecaille"'

1. 421P FOLFIRINOX with or without targeted therapy as first line for metastatic colorectal cancer: An AGEO multicenter real-world study

Author

Julien Taieb, C. Coutzac, P. McLellan, Pascal Artru, Yann Touchefeu, Christophe Locher, C. Torregrosa, S. Philonenko, E. Hafliger, Simon Pernot, Anthony Turpin, Valérie Moulin, M. Fonnesu, A. Drouillard, Romain Varnier, C. Toullec, Thierry Lecomte, and Cedric Lecaille

Subjects
Oncology, medicine.medical_specialty, FOLFIRINOX, Colorectal cancer, business.industry, medicine.medical_treatment, First line, Hematology, medicine.disease, Targeted therapy, Internal medicine, medicine, business
Published
2021

2. 435P Bevacizumab (bev) continuation with FOLFIRI or switch to aflibercept (afli) with FOLFIRI as second-line treatment (L2) after first line of FOLFOX-bev (L1) for metastatic colorectal cancer (mCRC): An AGEO multicenter study

Author

Anthony Turpin, Edouard Auclin, Christophe Locher, C. Torregrosa, L-J. Palmieri, E. Nassif, S. Racine Doat, A. Perret, Simon Pernot, Thierry Lecomte, B. Auberger, M. Jaffrelot, Cindy Neuzillet, T. Godet, Julien Taieb, Cedric Lecaille, Violaine Randrian, O. Bouche, Olivier Dubreuil, and David Sefrioui

Subjects
Oncology, medicine.medical_specialty, Second line treatment, Bevacizumab, business.industry, Colorectal cancer, First line, Hematology, medicine.disease, FOLFOX, Multicenter study, Internal medicine, FOLFIRI, Medicine, business, medicine.drug, Aflibercept
Published
2020

3. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Author

Josef Thaler, Richard Greil, Johannes Gaenzer, Wolfgang Eisterer, Joerg Tschmelitsch, Hellmut Samonigg, August Zabernigg, Franz Schmid, Günther Steger, Robert Steinacher, Johannes Andel, Alois Lang, Reinhold Függer, Friedrich Hofbauer, Ewald Woell, Dietmar Geissler, Alfred Lenauer, Manfred Prager, Jean-Luc Van Laethem, Eric Van Cutsem, Geert D'Haens, Gauthier Demolin, Joseph Kerger, Guido Deboever, Gilbert Ghillebert, Marc Polus, Hassan RezaieKalantari, Thierry Delaunoit, Jean Charles Goeminne, Marc Peeters, Philippe Vergauwe, Ghislain Houbiers, Yves Humblet, Jos Janssens, Dirk Schrijvers, Erik Vanderstraeten, Jan Vermorken, Daniel Van Daele, Michel Ferrante, Frederic Forget, Alain Hendlisz, Mette Yilmaz, Svend Erik Nielsen, Lene Vestermark, Jim Larsen, Marc Ychou, Ayman Zawadi, Mohamed-Ayman Zawadi, Olivier Bouche, Laurent Mineur, Jaafar Bennouna-Louridi, Louis Marie Dourthe, Eveline Boucher, Julien Taieb, Denis Pezet, Francoise Desseigne, Michel Ducreux, Patrick Texereau, Laurent Miglianico, Philippe Rougier, Serge Fratte, Charles-Briac Levache, Yacine Merrouche, Stephen Ellis, Christophe Locher, Jean-Francois Ramee, Claire Garnier, Frederic Viret, Bruno Chauffert, Isabelle Cojean-Zelek, Pierre Michel, Cedric Lecaille, Christian Borel, Jean-Francois Seitz, Denis Smith, Catherine Lombard-Bohas, Thierry Andre, Jean-Marc Gornet, Francine Fein, Marie-Aude Coulon-Sfairi, Marie-Christine Kaminsky, Jean-Paul Lagasse, Dominique Luet, Pierre-Luc Etienne, Mohamed Gasmi, Andre Vanoli, Suzanne Nguyen, Thomas Aparicio, Hervé Perrier, Noel Stremsdoerfer, Philippe Laplaige, Dominique Arsene, Dominique Auby, Laurent Bedenne, Romain Coriat, Bernard Denis, Patrick Geoffroy, Gilles Piot, Yves Becouarn, Gilbert Bordes, Gael Deplanque, Olivier Dupuis, Frederic Fruge, Rosine Guimbaud, Thierry Lecomte, Gérard Lledo, Iradej Sobhani, Amani Asnacios, Ahmed Azzedine, Christophe Desauw, Marie-Pierre Galais, Dany Gargot, You-Heng Lam, Abakar Abakar-Mahamat, Jean-Francois Berdah, Sylviane Catteau, Marie-Christine Clavero-Fabri, Jean-Francois Codoul, Jean-Louis Legoux, Denis Goldfain, Pierre Guichard, Denis Pere Verge, Jocelyne Provencal, Bruno Vedrenne, Catherine Brezault-Bonnet, Denis Cleau, Jean-Paul Desir, David Fallik, Bruno Garcia, Marie-Hélène Gaspard, Dominique Genet, Johannes Hartwig, Yves Krummel, Tamara MatysiakBudnik, Vanessa Palascak-Juif, Harizo Randrianarivelo, Yves Rinaldi, Albert Aleba, Ariane Darut-Jouve, Aimery de Gramont, Herve Hamon, Frederic Wendehenne, Axel Matzdorff, Michael Konrad Stahl, Wolfgang Schepp, Martin Burk, Lothar Mueller, Gunnar Folprecht, Michael Geissler, Luisa Mantovani-Loeffler, Thomas Hoehler, Walter Asperger, Hendrik Kroening, Ludwig Fischer von Weikersthal, Stefan Fuxius, Matthias Groschek, Johannes Meiler, Tanja Trarbach, Jacqueline Rauh, Nicolas Ziegenhagen, Albrecht Kretzschmar, Ullrich Graeven, Arnd Nusch, Goetz von Wichert, Ralf-Dieter Hofheinz, Gerhard Kleber, Karl-Heinz Schmidt, Ursula Vehling-Kaiser, Claudia Baum, Jochen Schuette, Georg Martin Haag, Wilhelm Holtkamp, Jochen Potenberg, Tobias Reiber, Georg Schliesser, Hans-Joachim Schmoll, Wolfgang Schneider-Kappus, Wolfgang Abenhardt, Claudio Denzlinger, Jan Henning, Bartscht Marxsen, Hans GuenterDerigs, Helmut Lambertz, Ingulf Becker-Boost, Karel Caca, Christian Constantin, Thomas Decker, Henning Eschenburg, Sigrun Gabius, Holger Hebart, Albrecht Hoffmeister, Heinz-August Horst, Stephan Kremers, Malte Leithaeuser, Sebastian Mueller, Siegfried Wagner, Severin Daum, Frank Schlegel, Martina Stauch, Volker Heinemann, Roberto Labianca, Giuseppe Colucci, Dino Amadori, Enrico Mini, Alfredo Falcone, Corrado Boni, Evaristo Maiello, Luciano Latini, Alberto Zaniboni, Giuseppe Aprile, Sandro Barni, Rodolfo Mattioli, Andrea Martoni, Rodolfo Passalacqua, Mario Nicolini, Enzo Pasquini, Carla Rabbi, Enrico Aitini, Alberto Ravaioli, Carlo Barone, Guido Biasco, Stefano Tamberi, Angelo Gambi, Claudio Verusio, Marina Marzola, Giorgio Lelli, Stefano Cascinu, Paolo Bidoli, Massimo Vaghi, Giorgio Cruciani, Francesco Di Costanzo, Alberto Sobrero, Roberto Petrioli, Massimo Aglietta, Oscar Alabiso, Federico Capuzzo, Domenico Cristi Corsi, Stefania Salvagni, Silvana Chiara, Francesco Ferraù, Francesco Giuliani, Sara Lonardi, Nicola Gebbia, Giovanni Mantovani, Evaristo Sanches, Juan Carlos Mellidez, Pedro Santos, Joao Freire, Cristina Sarmento, Luis Costa, Antonio Moreira Pinto, Sergio Barroso, Jorge Espirito Santo, Fátima Guedes, Amélia Monteiro, Anabela Sa, Irene Furtado, Josep Tabernero, Ramon Salazar, Enrique Aranda Aguilar, Fernando Rivera Herrero, Javier Sastre Valera, Manuel ValladaresAyerbes, Jaime FeliuBatlle, Silvia Gil, Carlos Garcia-Giron, Guillermo Lopez Vivanco, Antonia Salud Salvia, Vicente Alonso Orduña, Ruth Vera Garcia, Javier Gallego, Bartomeu Massuti Sureda, Jordi Remon, Maria Jose Safont Aguilera, Luis CireraNogueras, BernadoQueralt Merino, Cristina Gravalos Castro, Purificacion Martinez de Prado, Carlos PijaumePericay, Manuel ConstenlaFigueiras, InmaculadaGuasch Jordan, Maria Jose GomeReina, Amelia Lopez-Ladron Garcia, Antonio Arrivi Garcia-Ramos, Andres Cervantes, Carlos Fernandez Martos, Eugenio MarcuelloGaspar, Ines Cabezas Montero, Pilar Escudero Emperador, Ana Leon Carbonero, Manuel Gallen Castillo, Teresa Garcia Garcia, Jose Garcia Lopez, Encarnacion Gonzalez Flores, Monica GuillotMorales, Marta LlanosMuñoz, Ana López Martín, Joan Maurel, Juan Carlos Camara, Rosario Dueñas Garcia, Mercedes Salgado, Isabel HernandezBusquier, Teresa Checa Ruiz, Adelaida LacastaMuñoa, MiquelNogue Aliguer, Amalia Velasco Ortiz de Taranco, Miguel Mendez Ureña, Ferran Losa Gaspa, Jose Juan Ponce, Carlos Bosch Roig, Pedro Valero Jimenez, Antonio GalanBrotons, Santiago AlbiolRodriguez, Jose Ales Martinez, Liliana Canosa Ruiz, Margarita CentellesRuiz, John Bridgewater, Rob Glynne-Jones, Saad Tahir, Tamas Hickish, Jim Cassidy, and Leslie Samuel

Subjects
Oncology, Hematology
Published
2015

4. A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability

Author

Pascal Artru, Régis Cohen, Vincent Hautefeuille, Yann Touchefeu, Julien Taieb, Benjamin Sueur, Gael Goujon, Romain Coriat, Cedric Lecaille, Thomas Aparicio, Aurélie Ferru, G. Des Guetz, David Tougeron, C. de la Fouchardiere, T. Andre, A. Zaanan, Valérie Moulin, Lucie Gentilhomme, Thierry Lecomte, and David Sefrioui

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Colorectal cancer, business.industry, Microsatellite instability, Hematology, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Multicenter study, 030220 oncology & carcinogenesis, Internal medicine, medicine, business
Published
2017

5. End of life (EOL) chemotherapy (CT) in gastro-intestinal (GI) cancer patients (pts): A retrospective AGEO study

Author

Astrid Lièvre, Christophe Locher, Cedric Lecaille, Géraldine Perkins, Alexandra Lapeyre-Prost, A. Pozet, David Tougeron, H. Jaulmes-Bouillot, Julien Taieb, B. Landi, M. Vallee, M. Maillet, Florence Mary, F. Bonnetain, Johann Dreanic, Jean-Louis Legoux, and J.-M. Sabate

Subjects
Chemotherapy, medicine.medical_specialty, Oncology, business.industry, medicine.medical_treatment, Internal medicine, medicine, Hematology, business, Gi cancer, Gastroenterology, Gastro intestinal
Published
2016

6. PRODIGE 25 (FFCD 11-01) - Phase II randomized trial evaluating aflibercept associated with LV5FU2 regimen as first line treatment of non-resectable metastatic colorectal cancers (FOLFA)

Author

Jean-Louis Legoux, E. Maillard, Valérie Boige, Yann Touchefeu, Nicolas Barriere, M. Baconnier, Y. Rinaldi, Roger Faroux, Joëlle Egreteau, Thomas Aparicio, K. Le Malicot, S. Herrmann-Gandara, Cedric Lecaille, J. Raimbourg, and A. Vimal

Subjects
Oncology, medicine.medical_specialty, business.industry, Hematology, law.invention, First line treatment, Regimen, Randomized controlled trial, law, Internal medicine, Medicine, business, Aflibercept, medicine.drug
Published
2016

7. Perioperative Chemotherapy with Folfox in Resectable Gastro-Oesophageal Adenocarcinoma: An AGEO Multicentric Retrospective Study

Author

Florence, Mary, primary, Aziz, Zaanan, additional, David, Malka, additional, Pascal, Artru, additional, Marouane, Boubaya, additional, Emmanuelle, Samalin, additional, Romain, Coriat, additional, Baptiste, Bachet Jean, additional, David, Tougeron, additional, Mourad, Benallaoua, additional, Pauline, Afchain, additional, Christophe, Locher, additional, Isabelle, Baumgaertner, additional, Cedric, Lecaille, additional, and Thomas, Aparicio, additional

Published
2014
Full Text
View/download PDF

8. Folfirinox for Locally Advanced Pancreatic Adenocarcinoma. Results of an Ageo Multicenter Prospective Study

Author

Cedric Lecaille, Julien Taieb, Christelle De La Fouchardiere, Mélanie Gauthier, Jean-Frédéric Blanc, Anne Thirot-Bidault, David Malka, Franck Carbonnel, Lysiane Marthey, David Solub, Eric Francois, Romain Coriat, Isabelle Trouilloud, Jean-Baptiste Bachet, Antonio Sa-Cunha, Sylvain Manfredi, Eric Terrebonne, and Adèle Cueff

Subjects
medicine.medical_specialty, business.industry, FOLFIRINOX, Hematology, Gastroenterology, Gemcitabine, Surgery, Oxaliplatin, Irinotecan, Regimen, Oncology, Median follow-up, Internal medicine, Medicine, Folfirinox Regimen, Progression-free survival, business, medicine.drug
Abstract

Background The FOLFIRINOX regimen improves survival when compared to gemcitabine as first line treatment for patients (pts) with metastatic pancreatic cancer (1). There is no such data in non resecable, non metastatic, locally advanced pancreatic adenocarcinoma (LAPA). The aim of this study was to evaluate the safety and efficacy of FOLFIRINOX in this setting. Methods From February 2010 to February 2012, all pts from eleven French hospitals, who started FOLFIRINOX for a pathologically proven LAPA were included in a prospective database. Non resectability was determined by each local multidisciplinary staff. The absence of metastases was assessed by TAP CT-scans. FOLFIRINOX was administered every 2 weeks (oxaliplatin 85 mg/m2; irinotecan 180 mg/m2; leucovorin 400 mg/m2; fluorouracil 400 mg/m2 as bolus and 2400 mg/m2 as 46-hour continuous infusion). Results Seventy seven pts were enrolled. We report the preliminary analysis of the first 53 pts as data collection is still ongoing. Patients characteristics were M/F: 30/23; median age 63 (46-79); PS 0/1/2 : 24/28/1. twenty one pts had a bilary stent before starting treatment. The median number of cycles administered was 5 (1-30). There were no treatment-related deaths and 8% of pts stopped treatment because of toxicity. Grade 3-4 toxicities were neutropenia (15%), nausea (13%), diarrhea (8%), anemia (2%), and thrombopenia (2%). Grade 2-3 sensitive neuropathy occured in 19% of pts. Dose reduction was necessary in 28% and prophylactic GCSF was used in 86% of pts. Partial response rate was 30% [95 CI% 17%-43%], and 53% of pts showed stable disease [95% CI 39%-67%], resulting in a disease control rate of 83% [95% CI 73%-93%]. Closure external radiotherapy was performed in 62% of pts and 32% underwent surgical resection of their tumour. With a median follow up of 8.5 months [95% CI 7-11], median overall and progression free survivals have not been reached. One year overall and progression free survival rates were 80% [95% CI 57%-92%] and 54% [95% CI 29%-74%], respectively. Conclusion FOLFIRINOX in LAPA seems efficient with a manageable toxicity profile and led to secondary potentially curative surgery in approximately one third of the pts. These promising results are encouraging to test this regimen in a phase 3 trial. (1) Conroy et al. NEJM 2011; 364: 1817 Disclosure All authors have declared no conflicts of interest.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results